Blog
RSS FeedPosted by Michael Wonder on 25 Jul 2024
New clot busting drug recommended by NICE set to save NHS millions of pounds
24 July 2024 - Giving a new clot busting drug to people who have had a stroke could help save the ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 17 Jul 2024
CSL Behring announces positive reimbursement decision in Canada for Hemgenix (etranacogene dezaparvovec), the first gene therapy for haemophilia B
16 July 2024 - The positive decision from CADTH recognises the importance of this one-time, single dose innovative treatment for ...
Posted by Michael Wonder on 16 Jul 2024
SMC - July 2024 decisions
8 July 2024 - Voretigene neparvovec (Luxturna) was accepted for the treatment of adults and children with an extremely rare inherited ...
Posted by Michael Wonder on 10 Jul 2024
NICE recommends Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England in eligible adolescents and adults
10 July 2024 - Following approval of the European Commission (October 2023) and the MHRA (December 2023), lebrikizumab will be available ...
Posted by Michael Wonder on 10 Jul 2024
Lisocabtagene maraleucel for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
10 July 2024 - NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) ...
Posted by Michael Wonder on 03 Jul 2024
Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent
1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...
Posted by Michael Wonder on 29 Jun 2024
NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix
28 June 2024 - NICE has recommended CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) for immediate reimbursement by ...
Posted by Michael Wonder on 22 Jun 2024
NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults
21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment ...
Posted by Michael Wonder on 21 Jun 2024
Outcomes from the May 2024 PBAC intracycle meeting
21 June 2024 - Recommendations made by the PBAC in May 2024 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 19 Jun 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)
19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...
Posted by Michael Wonder on 13 Jun 2024
Baricitinib for the treatment of patients with juvenile idiopathic arthritis
13 June 2024 - NICE is unable to make a recommendation on the use in the NHS of baricitinib (Olumiant) for ...
Posted by Michael Wonder on 12 Jun 2024
Pembrolizumab in combination with trastuzumab and chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 June 2024 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with trastuzumab and ...
Posted by Michael Wonder on 12 Jun 2024
Voxelotor for the treatment of patients with haemolytic anaemia caused by sickle cell disease
12 June 2024 - NICE has published final evidence-based recommendations on the use of voxelotor (Oxbryta) for the treatment of ...
Posted by Michael Wonder on 10 Jun 2024
SMC - June 2024 decisions
10 June 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...